From initial FDA approvala
SINCE 2017, ≈253,000
PATIENTS HAVE FILLED AT
LEAST
1 DUPIXENT
PRESCRIPTIONb,c
a FDA approved since 2017 for adults, 2019 for adolescents (aged 12‑17 years), 2020 for children (aged 6-11 years),
and 2022 for infants to preschoolers (aged 6 months-5 years) with uncontrolled moderate‑to‑severe atopic dermatitis.
b IQVIA National Source of Business (NSOB) data as of April 2022.
c New adult and pediatric patients with uncontrolled moderate‑to‑severe atopic dermatitis.
It's Eczema
Awareness Month
Hear the stories
Get the stats
Take the Dx challenge
REVOLUTIONIZING THE TREATMENT FOR AD
prescribed
biologic
by dermatologists and
allergists in AD1,a
MORE THAN
1 MILLION PATIENTS
on therapy across approved
indications worldwide1,b
BEST
ACCESS
among specialty systemic
therapies indicated for AD1,c-e
atopic dermatitis
For patients with uncontrolled moderate-to-severe disease
First specialty systemic therapy with a phase 3 trial focused on hand and/or foot involvement (12+ years of age)
STRONG RECOMMENDATION FOR THE USE OF DUPIXENT IN AAD AND AAAAI/ACAAI JTF
AD GUIDELINES2,3,f
A part of your standard of care for appropriate uncontrolled moderate-to-severe AD patients
aIQVIA SMART Portal Patient Insights as of June 2025.
bThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, COPD, CRSwNP, CSU, PN, and EoE. Data through June 2025.
c≈99% of commercial AD patients (6+ months of age) nationally are covered for DUPIXENT. ≈93% of commercial AD patient lives have to fail only 1 or 2 prescription topical treatments.
dMMIT Analysis, June 2025. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.
eBased on available published commercial UM coverage criteria.
fInclusion in AAD and AAAAI/ACAAI AD Guidelines does not denote endorsement or recommendation of product use by AAD and AAAAI/ACAAI.
DUPIXENT HAS A DEMONSTRATED SAFETY PROFILE4
Most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.
Safety profile studied in >9000 patients across US‑approved indications4,g
gPatient total included patients in AD trials (SOLO 1, SOLO 2, CHRONOS, AD-1021, AD-1526, AD-1652, AD-1539, and AD-HAFT), asthma trials (DRI12544, QUEST, VENTURE, and VOYAGE), CRSwNP trials (SINUS-24 and SINUS-52), EoE trials (EoE-1 and EoE-2), PN trials (PRIME and PRIME2), COPD trials (BOREAS and NOTUS), CSU trials (CUPID-A, CUPID-B, and CUPID-C), and the BP trial (ADEPT).
OTHER CONSIDERATIONS
a biologic that is
NOT AN IMMUNOSUPPRESSANT
or a steroid4
NO KNOWN DRUG-TO-DRUG
INTERACTIONS4
Not metabolized through the liver or
excreted through the kidneys
NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING
according to the Prescribing Information4
NO boxed warning4
Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.
Select Important Safety Information
Warnings and Precautions
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
FIRST AND ONLY THERAPY TO TARGET IL-4Rα, THEREBY
SPECIFICALLY INHIBITING IL-4 AND IL-13 SIGNALING4
The mechanism of dupilumab action has not been definitively established.
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
AAAAI, American Academy of Allergy, Asthma, and Immunology; AAD, American Academy of Dermatology; ACAAI, American College of Allergy, Asthma, and Immunology; AD, atopic dermatitis; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis; JTF, Joint Task Force; PN, prurigo nodularis.